This HTML5 document contains 148 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00770/identifier/kegg-drug/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00770/identifier/iuphar/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00770/identifier/drugbank/
n33http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00770/identifier/guide-to-pharmacology/
n7http://linked.opendata.cz/resource/drugbank/company/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00770/identifier/national-drug-code-directory/
n9http://linked.opendata.cz/resource/drugbank/dosage/
n32http://linked.opendata.cz/resource/drugbank/mixture/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00770/identifier/chemspider/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00770/identifier/chebi/
n16http://www.rxlist.com/cgi/generic/
n8http://linked.opendata.cz/resource/drugbank/patent/
n30http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00770/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00770/identifier/pharmgkb/
n3http://linked.opendata.cz/ontology/drugbank/
n13http://www.drugs.com/cdi/
n31http://linked.opendata.cz/resource/drugbank/drug/DB00770/identifier/kegg-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
n19http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00770/identifier/pubchem-compound/
n6http://linked.opendata.cz/resource/atc/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00770/identifier/pubchem-substance/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00770
rdf:type
n3:Drug
n3:description
Alprostadil is produced endogenously and causes vasodilation by means of a direct effect on vascular and ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. This results in increased pulmonary or systemic blood flow in infants. In infants, it is used for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. In adults, it is used for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.
n3:dosage
n9:271B5D3B-363D-11E5-9242-09173F13E4C5 n9:271B5D3C-363D-11E5-9242-09173F13E4C5 n9:271B5D3D-363D-11E5-9242-09173F13E4C5 n9:271B5D3E-363D-11E5-9242-09173F13E4C5 n9:271B5D37-363D-11E5-9242-09173F13E4C5 n9:271B5D38-363D-11E5-9242-09173F13E4C5 n9:271B5D39-363D-11E5-9242-09173F13E4C5 n9:271B5D3A-363D-11E5-9242-09173F13E4C5 n9:271B5D36-363D-11E5-9242-09173F13E4C5 n9:271B5D34-363D-11E5-9242-09173F13E4C5 n9:271B5D35-363D-11E5-9242-09173F13E4C5 n9:271B5D3F-363D-11E5-9242-09173F13E4C5 n9:271B5D40-363D-11E5-9242-09173F13E4C5 n9:271B5D30-363D-11E5-9242-09173F13E4C5 n9:271B5D31-363D-11E5-9242-09173F13E4C5 n9:271B5D32-363D-11E5-9242-09173F13E4C5 n9:271B5D33-363D-11E5-9242-09173F13E4C5 n9:271B5D2F-363D-11E5-9242-09173F13E4C5
n3:group
approved investigational
n3:halfLife
5 to 10 minutes (after a single dose), in healthy adults and neonates.
n3:indication
For palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Also for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.
n3:manufacturer
n7:271B5D12-363D-11E5-9242-09173F13E4C5 n7:271B5D13-363D-11E5-9242-09173F13E4C5 n7:271B5D10-363D-11E5-9242-09173F13E4C5 n7:271B5D11-363D-11E5-9242-09173F13E4C5 n7:271B5D0E-363D-11E5-9242-09173F13E4C5 n7:271B5D0F-363D-11E5-9242-09173F13E4C5
owl:sameAs
n11:DB00770 n30:DB00770
dcterms:title
Alprostadil
adms:identifier
n15:Alprostadil n17:15544 n20:46508029 n21:PA448334 n22:5280723 n23:1882 n24:131636 n25:DB00770 n26:D00180 n28:0703-1501-02 n29:1882 n31:C04741
n3:mechanismOfAction
Alprostadil causes vasodilation by means of a direct effect on vascular and ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. This is because, as a form of prostaglandinE1 (PGE1) it has multiple effects on blood flow. This results in increased pulmonary or systemic blood flow in infants. In cyanotic congenital heart disease, alprostadil's actions result in an increased oxygen supply to the tissues. In infants with interrupted aortic arch or very severe aortic coarctation, alprostadil maintains distal aortic perfusion by permitting blood flow through the DA from the pulmonary artery to the aorta. In infants with aortic coarctation, alprostadil reduces aortic obstruction either by relaxing ductus tissue in the aortic wall or by increasing effective aortic diameter by dilating the DA. In infants with these aortic arch anomalies, systemic blood flow to the lower body is increased, improving tissue oxygen supply and renal perfusion. When administered by intracavernosal injection or as an intraurethral suppository, alprostadil acts locally to relax the trabecular smooth muscle of the corpora cavernosa and the cavernosal arteries. Swelling, elongation, and rigidity of the penis result when arterial blood rapidly flows into the corpus cavernosum to expand the lacunar spaces. The entrapped blood reduces the venous blood outflow as sinusoids compress against the tunica albuginea.
n3:packager
n7:271B5D0C-363D-11E5-9242-09173F13E4C5 n7:271B5D0D-363D-11E5-9242-09173F13E4C5 n7:271B5D0A-363D-11E5-9242-09173F13E4C5 n7:271B5D0B-363D-11E5-9242-09173F13E4C5 n7:271B5D08-363D-11E5-9242-09173F13E4C5 n7:271B5D09-363D-11E5-9242-09173F13E4C5 n7:271B5D06-363D-11E5-9242-09173F13E4C5 n7:271B5D07-363D-11E5-9242-09173F13E4C5 n7:271B5D04-363D-11E5-9242-09173F13E4C5 n7:271B5D05-363D-11E5-9242-09173F13E4C5 n7:271B5D02-363D-11E5-9242-09173F13E4C5 n7:271B5D03-363D-11E5-9242-09173F13E4C5 n7:271B5D01-363D-11E5-9242-09173F13E4C5
n3:patent
n8:1335346 n8:5773020 n8:5886039
n3:routeOfElimination
Alprostadil must be infused continuously because it is very rapidly metabolized. As much as 80% of the circulating alprostadil may be metabolized in one pass through the lungs, primarily by β- and ω-oxidation. The metabolites are excreted primarily by the kidney, and excretion is essentially complete within 24 hours after administration.
n3:synonym
(13e)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate Alprostadilum 11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid Edex Alprostadil Muse PGE1 α-CD Prostin vr PGE-1 Alprostadil Alfadex Caverject PGE₁ Befar (11alpha,13e,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid Prostaglandin e1
n3:toxicity
Oral, mouse: LD<sub>50</sub> = 186 mg/kg; Oral, rat: LD<sub>50</sub> = 228 mg/kg. Apnea, bradycardia, pyrexia, hypotension, and flushing may be signs of drug overdosage.
n5:hasAHFSCode
n33:24-12-92
n3:mixture
n32:271B5D00-363D-11E5-9242-09173F13E4C5 n32:271B5CFF-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
Bound in plasma primarily to albumin (81% bound) and to a lesser extent alpha-globulin IV-4 fraction (55% bound).
foaf:page
n13:alprostadil.html n16:alprostadil.htm n19:cav1073.shtml
n3:IUPAC-Name
n4:271B5D45-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5D4B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5D4A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5D47-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5D48-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5D49-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5D43-363D-11E5-9242-09173F13E4C5 n4:271B5D5B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5D41-363D-11E5-9242-09173F13E4C5 n4:271B5D44-363D-11E5-9242-09173F13E4C5 n4:271B5D5D-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5D42-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B5D5E-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n6:C01EA01 n6:G04BE01
n3:H-Bond-Acceptor-Count
n4:271B5D51-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5D52-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5D4C-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5D4D-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5D4F-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5D4E-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5D50-363D-11E5-9242-09173F13E4C5
n3:absorption
The absolute bioavailability of alprostadil has not been determined.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
745-65-3
n3:containedIn
n18:271B5D27-363D-11E5-9242-09173F13E4C5 n18:271B5D28-363D-11E5-9242-09173F13E4C5 n18:271B5D25-363D-11E5-9242-09173F13E4C5 n18:271B5D26-363D-11E5-9242-09173F13E4C5 n18:271B5D23-363D-11E5-9242-09173F13E4C5 n18:271B5D24-363D-11E5-9242-09173F13E4C5 n18:271B5D22-363D-11E5-9242-09173F13E4C5 n18:271B5D2D-363D-11E5-9242-09173F13E4C5 n18:271B5D2E-363D-11E5-9242-09173F13E4C5 n18:271B5D2B-363D-11E5-9242-09173F13E4C5 n18:271B5D16-363D-11E5-9242-09173F13E4C5 n18:271B5D2C-363D-11E5-9242-09173F13E4C5 n18:271B5D14-363D-11E5-9242-09173F13E4C5 n18:271B5D29-363D-11E5-9242-09173F13E4C5 n18:271B5D15-363D-11E5-9242-09173F13E4C5 n18:271B5D2A-363D-11E5-9242-09173F13E4C5 n18:271B5D18-363D-11E5-9242-09173F13E4C5 n18:271B5D19-363D-11E5-9242-09173F13E4C5 n18:271B5D17-363D-11E5-9242-09173F13E4C5 n18:271B5D20-363D-11E5-9242-09173F13E4C5 n18:271B5D21-363D-11E5-9242-09173F13E4C5 n18:271B5D1E-363D-11E5-9242-09173F13E4C5 n18:271B5D1F-363D-11E5-9242-09173F13E4C5 n18:271B5D1C-363D-11E5-9242-09173F13E4C5 n18:271B5D1D-363D-11E5-9242-09173F13E4C5 n18:271B5D1A-363D-11E5-9242-09173F13E4C5 n18:271B5D1B-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5D57-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5D59-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5D5A-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5D5C-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5D56-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5D55-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5D58-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5D46-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5D53-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5D54-363D-11E5-9242-09173F13E4C5